BackOrient EuroPharma , Ltd. Overview

Orient EuroPharma , Ltd. Profit Margin

Latest profit margin for Orient EuroPharma , Ltd.: -11.58% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-15.39%
↓ 279.16% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-11.58%
↓ 60.69% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Orient EuroPharma , Ltd. (4120.TWO) FAQ

Orient EuroPharma , Ltd. posts a profit margin of -11.58% as of June 2026. That compares with -7.2% in the prior-year period — down 60.7% year over year. That is below the sector sector average of 13.23%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Orient EuroPharma , Ltd.'s profit margin was -7.2%. The latest reading is -11.58% — a 60.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.23% is typical. Orient EuroPharma , Ltd.'s -11.58% is lower that level. That is roughly 187.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Orient EuroPharma , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -11.58% as of June 2026; use YoY and peer views to separate noise from signal.

Context for 4120.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.23%), and (3) consistency with growth and profitability. This page covers the first two; Orient EuroPharma , Ltd.'s other metric pages and overview cover the third.